Ben Tre Pharmaceutical JSC (STC:DBT) Debt-to-EBITDA : 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:DBT Ben Tre Pharmaceutical JSC STC:DBT
13 GF Score
Price ₫12,500.00
! 1 Warning Sign
View Full Analysis

What is Ben Tre Pharmaceutical JSC Debt-to-EBITDA?

Ben Tre Pharmaceutical JSC STC:DBT -0.79% 13 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates STC:DBT with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 690 Drug Manufacturers companies, Ben Tre Pharmaceutical JSC ranks worse than 144927.39% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ben Tre Pharmaceutical JSC's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. Ben Tre Pharmaceutical JSC's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was ₫0.00 Mil. Ben Tre Pharmaceutical JSC's annualized EBITDA for the quarter that ended in . 20 was ₫0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ben Tre Pharmaceutical JSC's Debt-to-EBITDA or its related term are showing as below:

STC:DBT's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.68
* Ranked among companies with meaningful Debt-to-EBITDA only.

Ben Tre Pharmaceutical JSC  (STC:DBT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Ben Tre Pharmaceutical JSC Debt-to-EBITDA Related Terms

Ben Tre Pharmaceutical JSC Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Ben Tre Pharmaceutical JSC's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ben Tre Pharmaceutical JSC Debt-to-EBITDA Chart

Ben Tre Pharmaceutical JSC Annual Data
Trend
Debt-to-EBITDA

Ben Tre Pharmaceutical JSC Semi-Annual Data
Debt-to-EBITDA

STC:DBT vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ben Tre Pharmaceutical JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ben Tre Pharmaceutical JSC Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ben Tre Pharmaceutical JSC's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ben Tre Pharmaceutical JSC's Debt-to-EBITDA falls into.


STC:DBT
13GF Score
Ben Tre Pharmaceutical JSC STC:DBT
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ben Tre Pharmaceutical JSC Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ben Tre Pharmaceutical JSC's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / N/A
=N/A

Ben Tre Pharmaceutical JSC's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
Ben Tre Pharmaceutical JSC (STC:DBT) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ben Tre Pharmaceutical JSC. According to the industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Ben Tre Pharmaceutical JSC's Debt-to-EBITDA too high?
Ben Tre Pharmaceutical JSC's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 690 companies for Debt-to-EBITDA. This places Ben Tre Pharmaceutical JSC in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ben Tre Pharmaceutical JSC. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ben Tre Pharmaceutical JSC's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Ben Tre Pharmaceutical JSC's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ben Tre Pharmaceutical JSC Business Description

Address No. 6A3, National Highway 60, Phu Tan Ward, Vinh Long Province, Ben Tre, VNM
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
13GF Score

Get the complete analysis for STC:DBT

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫12,500.00
Price